Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials

• Published in: BMJ open Vol. 12; no. 3; p. e048502
• Main Authors: Izcovich, Ariel, Siemieniuk, Reed Alexander, Bartoszko, Jessica Julia, Ge, Long, Zeraatkar, Dena, Kum, Elena, Qasim, Anila, Khamis, Assem M, Rochwerg, Bram, Agoritsas, Thomas, Chu, Derek K, McLeod, Shelley L, Mustafa, Reem A, Vandvik, Per, Brignardello-Petersen, Romina
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 02.03.2022; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Adenosine Monophosphate - adverse effects; Adenosine Monophosphate - analogs & derivatives; adverse events; Alanine - adverse effects; Alanine - analogs & derivatives; Antiretroviral drugs; Antiviral drugs; Asian literature; Bias; Calibration; Chinese literature; COVID-19; COVID-19 - drug therapy; Creatinine; Drug Combinations; Drugs; Humans; Hydroxychloroquine - adverse effects; Infectious Diseases; Information sources; Intervention; Kidneys; Lopinavir - adverse effects; Medical research; Randomized Controlled Trials as Topic; Ritonavir - adverse effects; SARS-CoV-2; Systematic review; Toxicity; COVID-19; infectious diseases; adverse events
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2020-048502

BackgroundTo summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19.MethodsWe searched 32 databases through 27 October 2020. We included randomised trials comparing any of the drugs of interest to placebo or standard care, or against each other. We conducted fixed-effects pairwise meta-analysis and assessed the certainty of evidence using the grading of recommendations assessment, development and evaluation approach.ResultsWe included 16 randomised trials which enrolled 8152 patients. For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty. Compared with standard care or placebo, low certainty evidence suggests that remdesivir may not have an important effect on acute kidney injury (risk difference (RD) 8 fewer per 1000, 95% CI 27 fewer to 21 more) or cognitive dysfunction/delirium (RD 3 more per 1000, 95% CI 12 fewer to 19 more). Low certainty evidence suggests that hydroxychloroquine may increase the risk of cardiac toxicity (RD 10 more per 1000, 95% CI 0 more to 30 more) and cognitive dysfunction/delirium (RD 33 more per 1000, 95% CI 18 fewer to 84 more), whereas moderate certainty evidence suggests hydroxychloroquine probably increases the risk of diarrhoea (RD 106 more per 1000, 95% CI 48 more to 175 more) and nausea and/or vomiting (RD 62 more per 1000, 95% CI 23 more to 110 more) compared with standard care or placebo. Low certainty evidence suggests lopinavir/ritonavir may increase the risk of diarrhoea (RD 168 more per 1000, 95% CI 58 more to 330 more) and nausea and/or vomiting (RD 160 more per 1000, 95% CI 100 more to 210 more) compared with standard care or placebo.DiscussionHydroxychloroquine probably increases the risk of diarrhoea and nausea and/or vomiting and may increase the risk of cardiac toxicity and cognitive dysfunction/delirium. Lopinavir/ritonavir may increase the risk of diarrhoea and nausea and/or vomiting. Remdesivir may have no important effect on risk of acute kidney injury or cognitive dysfunction/delirium. These findings provide important information to support the development of evidence-based management strategies for patients with COVID-19.